Thread by @StevenBremMD

Delighted that the Editorial Board of @NeurologyToday, the news source of the AAN, @AANmember, selected our dendritic cell vaccine trial, led by Dr. Linda Liau, as one of the "Best Advances of 2022." #immunotherapy @PennNeurology @PennNSG @PennCancer

pubmed.ncbi.nlm.nih.gov/36394838/

The article notes Median OS for 232 patients with nGBM on DCVax = 19.3M from randomization (22.4M from surgery) vs 16.5M from controls; Survival at 48 M = 15.7% vs 9.9%; mOS at 60M, 13.0M vs 5.7%. Survival for 64 patients with rGBM =13.2M vs. 7.8 M, controls. At 24M, 20.7 vs 9.6%

At 30M, survival was 11.1 vs 5.1% (controls). The study is deemed important because: i) addition of DCVax to SOC resulted in clinically meaningful and statistically significant extension of survival compared to matched, contemporaneous, external controls receiving SOC alone.

ii) noteworthy tails of long-term survivors; iii) novel elements including: a) trial design with external matched controls; b) therapy based on the concept of provoking a broader, anti-tumor immune response than is available from conventional therapies of checkpoint blockade

Analysis reported independently by Amy A. Pruitt, MD, FAAN, William N. Kelley Professor of Neurology, University of Pennsylvania, an esteemed colleague, master clinician, an extraordinary educator, and a true pioneer in neuro-oncology. Kudos! #Neurology #Pennneurology